These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 3156025

  • 1. Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.
    Cullmann W, Stieglitz M, Baars B, Opferkuch W.
    Chemotherapy; 1985; 31(1):19-28. PubMed ID: 3156025
    [Abstract] [Full Text] [Related]

  • 2. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R, Michéa-Hamzehpour M, Pechère JC.
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [Abstract] [Full Text] [Related]

  • 3. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM, Baltch AL, Smith RP.
    J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
    [Abstract] [Full Text] [Related]

  • 4. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    Guimaraes MA, Noone P.
    J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
    [Abstract] [Full Text] [Related]

  • 5. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A, Phillips I.
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [Abstract] [Full Text] [Related]

  • 6. Comparative in vitro activity of three new quinolone antibiotics against recent clinical isolates.
    Forsgren A.
    Scand J Infect Dis; 1985 Nov; 17(1):91-4. PubMed ID: 3158070
    [Abstract] [Full Text] [Related]

  • 7. In vitro activity of enoxacin compared with norfloxacin and amikacin.
    van der Auwera P, de Moor G, Lacroix G, Mambour A, Rossion N, Schuyteneer F.
    Eur J Clin Microbiol; 1985 Feb; 4(1):55-8. PubMed ID: 3157568
    [Abstract] [Full Text] [Related]

  • 8. Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin.
    Kresken M, Wiedemann B.
    Antimicrob Agents Chemother; 1988 Aug; 32(8):1285-8. PubMed ID: 3142353
    [Abstract] [Full Text] [Related]

  • 9. Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.
    Barry AL, Jones RN.
    Antimicrob Agents Chemother; 1984 Jun; 25(6):775-7. PubMed ID: 6234858
    [Abstract] [Full Text] [Related]

  • 10. Comparative in vitro activities of pefloxacin, ofloxacin, enoxacin and ciprofloxacin against 256 clinical isolates.
    Arpi M, Gahrn-Hansen B, Søgaard P, Bentzon MW.
    Acta Pathol Microbiol Immunol Scand B; 1987 Apr; 95(2):141-6. PubMed ID: 3473910
    [Abstract] [Full Text] [Related]

  • 11. A laboratory assessment of ciprofloxacin and comparable antimicrobial agents.
    Shrire L, Saunders J, Traynor R, Koornhof HJ.
    Eur J Clin Microbiol; 1984 Aug; 3(4):328-32. PubMed ID: 6237900
    [Abstract] [Full Text] [Related]

  • 12. In vitro activity of the new 4-quinolone compound Ro 23-6240.
    Clarke AM, Zemcov SJ.
    Eur J Clin Microbiol; 1987 Apr; 6(2):161-4. PubMed ID: 3109895
    [Abstract] [Full Text] [Related]

  • 13. The sensitivity of gram-negative and gram-positive bacteria to ofloxacin.
    Speciale A, Stefani S, Caccamo F, Nicolosi VM, Nicoletti G.
    Chemioterapia; 1987 Feb; 6(1):17-22. PubMed ID: 3470153
    [Abstract] [Full Text] [Related]

  • 14. The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.
    King A, Shannon K, Phillips I.
    J Antimicrob Chemother; 1984 Apr; 13(4):325-31. PubMed ID: 6233249
    [Abstract] [Full Text] [Related]

  • 15. The comparative activity of twelve 4-quinolone antimicrobials against Haemophilus influenzae and Streptococcus pneumoniae.
    Ridgway GL, O'Hare MD, Felmingham D, Grüneberg RN.
    Drugs Exp Clin Res; 1985 Apr; 11(4):259-62. PubMed ID: 2941258
    [Abstract] [Full Text] [Related]

  • 16. Frequency and expression of mutational resistance to the 4-quinolone antibacterials.
    Smith JT.
    Scand J Infect Dis Suppl; 1986 Apr; 49():115-23. PubMed ID: 3547618
    [Abstract] [Full Text] [Related]

  • 17. Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.
    Sanders CC, Sanders WE, Goering RV, Werner V.
    Antimicrob Agents Chemother; 1984 Dec; 26(6):797-801. PubMed ID: 6098219
    [Abstract] [Full Text] [Related]

  • 18. [In vitro activity of seven gyrase inhibitors of a group of heterocyclic carbonic acids against nonfermenting gram negative rods (nonfermenters)].
    Grimm H.
    Arzneimittelforschung; 1985 Dec; 35(3):570-2. PubMed ID: 2986655
    [Abstract] [Full Text] [Related]

  • 19. In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.
    Smith SM.
    Antimicrob Agents Chemother; 1986 Feb; 29(2):325-6. PubMed ID: 2940966
    [Abstract] [Full Text] [Related]

  • 20. The in-vitro activity of EN 272, a quinolone-7-carboxylic acid, in comparison with other quinolones.
    Neu HC.
    J Antimicrob Chemother; 1985 Jul; 16(1):43-8. PubMed ID: 3862659
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.